Sibutramine. A review of its contribution to the management of obesity.
about
Pharmacological targeting of the serotonergic system for the treatment of obesityObesity pharmacotherapy: current perspectives and future directionsSibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide YSibutramine effects on central mechanisms regulating energy homeostasisSibutramine treatment in obesity: predictors of weight loss including rorschach personality data.Treating obese patients with poorly controlled diabetes: confessions of an insulin therapist.Effects of a stimulant-free dietary supplement on body weight and fat loss in obese adults: a six-week exploratory study.Antiobesity pharmacotherapy in the management of type 2 diabetes.5-HT2C receptor modulation and the treatment of obesity.Safety of antiobesity drugs.Rise and fall of anti-obesity drugs.Prevalence of legal and illegal stimulating agents in sports.Insulin resistance and beta-cell dysfunction as therapeutic targets in type 2 diabetes.Pharmacological treatment of obesity in children and adolescents: present and futureThe use of animal models in expression pharmacogenomic analyses.Sibutramine-associated adverse effects: a practical guide for its safe use.Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.The use of serotonergic drugs to treat obesity--is there any hope?An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.Pharmacological management of obesity.Contemporary approaches into obesity: drugs and genes.Anti-hyperlipidemic effect of soybean extract fermented by Bacillus subtilis MORI in db/db mice.Optimal diabetes management during medical weight loss for cardiovascular risk reduction.Sibutramine on cardiovascular outcome.Randomized clinical trials of weight loss maintenance: a review.The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.Anti-obesity drugs: past, present and future.Pharmacological management of obese child.Antiobesity carbonic anhydrase inhibitors: a literature and patent review.Reducing the risk of obesity: defining the role of weight loss drugs.New pharmacological treatments for the management of obesity.Sibutramine (reductil®)-induced cutaneous leukocytoclastic vasculitis: a case reportOptimization of the preparation of fish protein anti-obesity hydrolysates using response surface methodology.The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour.Absence of sibutramine effect on spontaneous anxiety in rats.Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.Combined dietary and pharmacological weight management in obese hypopituitary patients.Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.Sibutramine promotes amygdala activity under fasting conditions in obese women.
P2860
Q24658013-B0D0B841-13CE-44A2-BC1C-69D8691351D8Q26828559-D83EBBAF-E8F6-41BA-AACD-CB38A5F13F9CQ28363106-6CF6F9EA-34F6-431E-BEB8-207810D46405Q30420884-BD2B8266-5070-42A1-96E2-347FE1CB46BDQ33195173-C47B91A7-3E81-4AC7-A126-EB2F98EE3BDBQ33707387-BD302B58-F28F-4D1D-B2F8-26A9BB1789CFQ33738882-342715D7-5C97-4794-AD2F-238908BF8ACAQ33883725-4CD57354-C9FB-4383-8788-A8BDAD6925B2Q33936081-09F2FFD8-5B34-431D-A4F9-C457748F0596Q34016243-B0085ADA-5144-416A-B0E5-FBC91C81B822Q34026742-1F8FECE5-60AC-4D21-ACCB-9B3EF735574AQ34177175-AE0FB8C0-64CF-4F48-8FEE-31A5854D4293Q34344990-F0DFC5FC-9841-4BC5-8932-4522DB4E8AF9Q34442880-C423CCA5-40B4-461F-AB08-0C366941831CQ34576928-E1021349-5CFA-4405-8418-DAC6FA8F5D58Q34585304-C48E310C-5AB8-4BF4-BD89-32E52475DAF8Q34661571-F79330E4-3AF9-4006-AFF4-DF89CDB598E4Q34712327-AAFBE59E-90FB-44E1-AEBA-FEADD27F5780Q34742716-3EAACBAB-AA9F-483E-8B40-FA711104DE2CQ35020527-40473B62-AA08-47DF-8AC5-D7F78FD6DC57Q35992004-703DE376-4E21-4631-862A-ED4C34A1D009Q36076549-C71338A7-4D26-455F-A3E4-668BBCCD6D0FQ36216869-6E71604F-21DD-4B33-9986-CD88E7387A49Q36783695-0CE78D28-FE74-4047-AC6F-7EDCF6BDC13EQ37177953-D9CA1866-5EDE-4BDF-8645-C04BCB917E8AQ37226372-EC284E26-C040-4457-AC56-87EB4758D3A7Q38036925-8E654D6A-6DA1-4297-8AFD-F2213DB706E9Q38087903-3A6C0076-7027-4C3F-86C1-2F7C23F43D29Q38100815-02B2BA69-4ABF-4356-B73E-7F188E9C41D0Q38109836-D4E5CCF8-43E3-4C38-8216-3E4219B6414AQ38211754-A1BE2AEE-8079-4964-B316-63BDB2F39D55Q39577175-3468F9EB-CDFD-48A5-9A1C-80BE3F40236DQ41616972-17416185-AF2D-4CFA-BC1C-CA7708DF7591Q41910031-EBCB7F17-1D9B-4ACF-B63F-378900B44FAEQ42972169-26F06CB8-70CB-4BC6-8248-7504A7F86D0EQ43902773-20E10069-66F8-4B75-8183-36B824907A58Q44584072-3B500FE2-0DA7-41CA-A475-B7955CECBC07Q45188956-FAA70F5F-CA4F-41E9-B591-67ABACC388CAQ47218179-A1CA8799-6CBB-44F9-9266-FD6059170D29Q48021282-155A9D67-004F-45BC-B868-8EB1E70BF3E3
P2860
Sibutramine. A review of its contribution to the management of obesity.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Sibutramine. A review of its contribution to the management of obesity.
@en
Sibutramine. A review of its contribution to the management of obesity.
@nl
type
label
Sibutramine. A review of its contribution to the management of obesity.
@en
Sibutramine. A review of its contribution to the management of obesity.
@nl
prefLabel
Sibutramine. A review of its contribution to the management of obesity.
@en
Sibutramine. A review of its contribution to the management of obesity.
@nl
P1433
P1476
Sibutramine. A review of its contribution to the management of obesity.
@en
P2093
P304
P356
10.2165/00003495-199856060-00019
P577
1998-12-01T00:00:00Z
P6179
1050178523